Nice write-up in Emerging Growth Stocks by Lou Paquette.
I will include a few excerpts from his paid newsletter but in fairness to someone doing business I won't reproduce the whole article here. One can get the issue on a Pay-for-view basis at www.stockhouse.com
"Promising new breast cancer diagnostic, less toxic therapeutic in the making
Shares fully diluted: 7.2 million
52 Wk H.-L.: $7.00 - $2.00
Price Sept. 17/99: $2.50
Sneak Previewed May '99 Issue $3.00
BILB stock has gone sideways since we sneak previewed this breast cancer research company in the May issue. I have continued monitoring the company, and have come to the conclusion that their prospects remain exciting, and that some of the reasons for the mild price weakness lately are temporary and non-material, in other words, potentially a good time to take a serious look at this one.........
Women without mammastatin get breast cancer
It's an amazingly simple story. Mammastatin is a protein in the blood that controls abnormal cell growth in breast tissue. It's present in healthy women, and absent or sharply reduced in 90% of women with breast cancer. Hence, there are three important potential uses for Mammastatin. One as a diagnostic, second as a therapy, and thirdly as a preventative.
If women without Mammastatin protein get breast cancer, testing for it could make for an inexpensive, effective alternative complimentary diagnostic tool. Then again, what would adding Mammastatin do for women who have already developed breast cancer? Finally, if a woman is free of breast cancer, but showing dangerously low levels of the stuff, maybe, it could actually be used to prevent cancer in women someday! That's tremendous potential for just one protein.
Progress to date
I am most familiar with the therapeutic, which is also exciting because it should be far less damaging to patients than traditional chemotherapy treatments. Chemo indiscriminately destroys cells throughout the body, this sounds far more like a magic bullet that only affects targeted cancer cells. To date, research on 29 late stage cancer patients injecting Mammastatin has been 70% effective in preventing breast cancer growth.
Phase l & ll human clinical trials on the first six (12 now) of thirty-six patients began at the U. of Texas M.D. Anderson Cancer Center in Houston in July"
Louis Paquette
Publisher
EMERGING GROWTH STOCKS (EGS)
"Mining for Profits on the Internet"
102 - 2020 Comox Street,
Vancouver, B.C. V6G 1R9
(604) 687-5772
www.stockhouse.com (newsletter section)
www.infomine.com
--------------------------------------------------
Mr. Paquette went into greater details about targets and future financings etc.
I have read the EGS for the last couple of years and can say that some of the picks there have been nothing short of remarkable, stox.com and GIV:VSE the first coming to mind.
I also saw that Danny Deadlock has recently mentioned Biolabs again and I am hoping that a restoration of the OTCBB coupled with any company news releases and the renewed newsletter interest could stimulate the stock once more. |
